Pricing PowerNarrow moat

During the life of a patent, a drugmaker enjoys pricing power of a kind few businesses ever see: with no substitute permitted and a product that may be medically essential, the seller can price closer to the value the drug delivers than to the cost of making it. A pill that costs pennies to manufacture but transforms a patient's health can command a price of hundreds or thousands of dollars a month, and for a patent-protected medicine with no direct competitor, there is little to stop it. This is the source of pharmaceutical profitability.

The power is amplified by how medicine is paid for. Because insurers, governments, and employers — not patients directly — foot most of the bill, and because the alternative to an effective drug can be hospitalization, disability, or death, demand is unusually insensitive to price. A patient who needs a drug needs it, and a payer covering a population will pay for a treatment that works. Lilly's best drugs sit in exactly this position: essential, protected, and reimbursed, which is why they earn the margins they do.

The growing constraint is that this pricing power, long nearly unchecked in the United States, is now under real political and structural pressure. Drug pricing has become a potent political issue, governments negotiate harder, and Medicare has, for the first time, gained the power to negotiate prices on certain drugs. Pricing power remains a genuine and enormous advantage within the patent window, but it is no longer the blank check it once was, and the direction of policy — in the US as elsewhere, with Medicare's negotiated prices now phasing in under the IRA¹ — is toward paying drugmakers less.